The company’s four advanced programs include ICA-17043, an inhibitor of the Gardos channel, for the chronic treatment of sickle cell disease, which is in Phase III clinical trials; a lead compounds for epilepsy and neuropathic pain, which is under preclinical studies; a compound for atrial fibrillation, which is being developed by its collaborator Bristol-Myers Squibb Company and is in phase I clinical trials; and a compound for dementia, including Alzheimer’s disease, which is being developed by its collaborator Yamanouchi Pharmaceutical Co.
, Ltd.
and is undergoing advanced preclinical testing.
In addition, it conducts drug discovery programs focused on new therapeutics for pain disorders, inflammatory disorders, and glaucoma.
Icagen has collaboration and copromotion agreements with McNeil Consumer & Specialty Pharmaceuticals Division of McNeil-PPC, Inc.
relating to the development and commercialization of ICA-17043; and with Abbott Laboratories to discover, develop, and market compounds that act on specified ion channel targets for the treatment of neuropathic pain and with application in urology, including the treatment of urinary incontinence.
The company was co-founded by P.
Kay Wagoner and H.
Jefferson Leighton.
It was incorporated in 1992 and is based in Durham, North Carolina.
